Breathing is life, but for millions of people living with lung diseases, each breath can be a constant struggle. These…
This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology…
Published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), results of a VHIO-led study…
Led by Thierry Andre, Head of the Department of Medical Oncology at the Hôpital Saint Antoine in Paris, the phase…
Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the…
The journal Nature has published the results of a clinical trial led by researchers from the Clínica Universidad de Navarra…
The phase 3 EMBER-3 trial is evaluating imlunestrant, a next-generation oral selective estrogen receptor degrader (SERD), alone or in combination…
The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard…
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second-leading cause of cancer-related deaths in Europe by 2040. Unlike other…
A recent study has provided new insights into how the tumour microenvironment may affect the development of liver metastases in…
The Vall d’Hebron Institute of Oncology (VHIO) has received one of the COFUND grants under the Marie Skłodowska-Curie Actions (MSCA)…
“Maestra con clase” is an initiative created by Mónica Tribó to design materials and products specifically for teachers. In her…
